Molecular imaging and treatment of PSMA-positive prostate cancer with 99mTc radiolabeled aptamer-siRNA chimeras
- 1 January 2022
- journal article
- research article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 104-105, 28-37
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81671714, 81771864)
This publication has 31 references indexed in Scilit:
- STAT3 regulated ARF expression suppresses prostate cancer metastasisNature Communications, 2015
- Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate ThemEuropean Urology, 2015
- Enhanced therapeutic effect of cisplatin on the prostate cancer in tumor-bearing mice by transfecting the attenuated Salmonella carrying a plasmid co-expressing p53 gene and mdm2 siRNACancer Letters, 2013
- Mdm2 and Tumorigenesis: Evolving Theories and Unsolved MysteriesGenes & Cancer, 2012
- The suppression of prostate LNCaP cancer cells growth by Selenium nanoparticles through Akt/Mdm2/AR controlled apoptosisBiomaterials, 2011
- Molecular Imaging of MDM2 Messenger RNA with 99mTc-Labeled Antisense Oligonucleotides in Experimental Human Breast Cancer XenograftsJournal of Nuclear Medicine, 2010
- Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumorsNature Biotechnology, 2009
- Chemical Modification of siRNAs for In Vivo UseOligonucleotides, 2008
- Effect of asymmetric terminal structures of short RNA duplexes on the RNA interference activity and strand selectionNucleic Acids Research, 2008
- Cell type–specific delivery of siRNAs with aptamer-siRNA chimerasNature Biotechnology, 2006